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Background: Heparin cofactor II (HCII) is a circulating protease inhibitor, one which contains an N-terminal acidic
extension (HCII 1-75) unique within the serpin superfamily. Deletion of HCII 1-75 greatly reduces the ability of
glycosaminoglycans (GAGs) to accelerate the inhibition of thrombin, and abrogates HCII binding to thrombin
exosite 1. While a minor portion of HCII 1-75 can be visualized in a crystallized HCII-thrombin S195A complex, the
role of the rest of the extension is not well understood and the affinity of the HCII 1-75 interaction has not been
quantitatively characterized. To address these issues, we expressed HCII 1-75 as a small, N-terminally hexahistidine-
tagged polypeptide in E. coli.
Results: Immobilized purified HCII 1-75 bound active α-thrombin and active-site inhibited FPR-ck- or S195A-
thrombin, but not exosite-1-disrupted γT-thrombin, in microtiter plate assays. Biotinylated HCII 1-75 immobilized on
streptavidin chips bound α-thrombin and FPR-ck-thrombin with similar KD values of 330-340 nM. HCII 1-75
competed thrombin binding to chip-immobilized HCII 1-75 more effectively than HCII 54-75 but less effectively
than the C-terminal dodecapeptide of hirudin (mean Ki values of 2.6, 8.5, and 0.29 μM, respectively). This superiority
over HCII 54-75 was also demonstrated in plasma clotting assays and in competing the heparin-catalysed inhibition
of thrombin by plasma-derived HCII; HCII 1-53 had no effect in either assay. Molecular modelling of HCII 1-75
correctly predicted those portions of the acidic extension that had been previously visualized in crystal structures,
and suggested that an α-helix found between residues 26 and 36 stabilizes one found between residues 61-67. The
latter region has been previously shown by deletion mutagenesis and crystallography to play a crucial role in the
binding of HCII to thrombin exosite 1.
Conclusions: Assuming that the KD value for HCII 1-75 of 330-340 nM faithfully predicts that of this region in intact
HCII, and that 1-75 binding to exosite 1 is GAG-dependent, our results support a model in which thrombin first
binds to GAGs, followed by HCII addition to the ternary complex and release of HCII 1-75 for exosite 1 binding and
serpin mechanism inhibition. They further suggest that, in isolated or transferred form, the entire HCII 1-75 region is
required to ensure maximal binding of thrombin exosite 1.
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Heparin cofactor II (HCII) is a 66 kDa plasma protein and
member of the serpin superfamily of protease inhibitors
[1,2] (reviewed in [3]). It regulates the key coagulation pro-
tease thrombin by trapping it in a covalently-linked
denaturation-resistant complex. Thrombin-complexed HCII
is cleaved at its reactive center peptide bond [4], while
thrombin in the inhibitory complex, by analogy to enzymes
in other serpin-enzyme complexes, is conformationally
inactivated by active site distortions that render it incapable
of completing the catalytic cycle of a proteolytic enzyme
[5,6]. The rate of inhibition of thrombin by HCII is in-
creased by three to four orders of magnitude by glycosami-
noglycans (GAGs) such as heparin, heparan sulfate, or
dermatan sulfate [7-11]. The predominant mechanism of
GAG acceleration of thrombin inhibition by HCII appears
to be allosteric [12-14], although longer GAG chains may
have a higher affinity for thrombin than for HCII, introdu-
cing some template effects [15]. GAG binding elicits a con-
formational change in HCII that enables a region of this
serpin inhibitor to bind thrombin anion-binding exosite 1,
a cluster of charged residues which also engages fibrinogen,
thrombomodulin, factor V, and the carboxy-terminal por-
tion of the leech thrombin inhibitor hirudin [16].
Alignment of the primary structure of HCII to other
serpins [17] revealed the presence of a unique 75 amino
acid N-terminal extension of the protein, one characterized
by two repeated negatively charged regions containing 14
glutamic or aspartic acid residues and 2 sulfated tyrosines
between positions 42 and 75 of the polypeptide. Deletion
of residues 1-67 or 1-74 greatly reduced GAG-catalyzed
thrombin inhibition by HCII, while having little effect on
progressive, GAG-independent inhibition; deletion of resi-
dues 1-52 affected neither mode of inhibition [7]. Charge
neutralization of the GAG binding domain in HCII helix D
was found to activate HCII for thrombin inhibition in the
absence of GAGs [10,11]. Substitution of γT-thrombin, in
which exosite 1 has been largely disrupted by proteolysis,
for intact α-thrombin in HCII inhibition studies was shown
to eliminate most of the GAG-dependent acceleration
[7,9,11,18]. These observations were unified in models of
HCII inactivation in which GAG binding releases both the
N-terminal extension for exosite 1 binding and the reactive
centre loop for engagement with the active site of throm-
bin [7,10,11,18].
Previous work from this laboratory showed that fusion
of residues 1-75 of HCII to the N-terminus of another
thrombin inhibitory serpin, the M358R “Pittsburgh” vari-
ant of α1-proteinase inhibitor (α1-PI, also known as α1-
antitrypsin) increased the rate of thrombin inhibition in
the absence of GAGs by 21-fold [19]. The rate advantage
of the HAPI M358R fusion protein over unfused α1-PI
M358R was reduced to 6-fold when residues 55-75 were
substituted for the entire N-terminal acidic extension,and eliminated altogether either when all acidic residues
between 55-75 were neutralized by mutation in the full
1-75 transferred extension, or when residues 1-54
alone were employed for fusion [19]. The rate advan-
tage was also reduced to 9-fold for γT-thrombin versus
intact α-thrombin, and was less than 2-fold for inhibition
of trypsin or activated protein C [19].
Although HCII has been crystallized both alone and in
an encounter complex with S195A-thrombin, the N-
terminal acidic extension could not be visualized in the
native HCII structure, and was only partially resolved in
the HCII-S195A complex, in which residues 56 to 72 were
found to form extensive hydrophobic and some electro-
static bonds with thrombin exosite 1 [20]. Although the
differences between the encounter complex and the native
structure support the allosteric model of activation, they
provide no information on the position or role of the first
54 residues of HCII. Moreover, with the exception of one
study employing a synthetic peptide to HCII residues 54-
75, which showed inhibition of thrombin-mediated fi-
brinogen cleavage and clot formation [21], there is little
information available in the literature addressing the affi-
nity of binding of the HCII N-terminal extension to
thrombin. In the current study, we expressed HCII 1-75
as a hexahistidine-tagged small recombinant polypeptide
in E. coli and examined its binding to various forms of
thrombin in comparison to HCII 1-53 and 54-75, as well
as to peptides corresponding to the C-terminus of hirudin.
We report a higher affinity between thrombin and HCII
1-75 than in the case of HCII 54-75, consistent with our
previous findings with α1-PI M358R fusion proteins [19];
in addition we report KD values for the HCII 1-75 and
thrombin interaction in the 300 nM range.
Methods
Peptides
Synthetic peptides corresponding to residues 1-53 and
54-75 of HCII, both preceded by MGSH6 sequences
with unmodified amino termini, were prepared by the
Advanced Protein Technology Centre of the Hospital for Sick
Children, Toronto, ON, using 9-fluorenylmethyloxycarbonyl
(Fmoc) chemistry and solid phase synthesis. Peptides cor-
responding to hirudin variant 1 residues 55-65 with an
acetylated N-terminus, and residues 54-65 with a free
N-terminus and tyrosine sulfation of residue Y63 were
purchased from Sigma Aldrich (St. Louis, MO).
Construction of pBAD-H6-HCII1-75
In order to express HCII 1-75 as an independent poly-
peptide unconnected to the rest of the HCII protein,
plasmid pBAD-H6-API M358R [22] was used as the tem-
plate for PCR, employing sense oligonucleotide 5’-
GATCCATGGG GTCTCATCAC CATCACCATC ACG
GGAGCAA AGGCCCGCTG GATCAG-3’ [23] and
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TGTA GTCGTCGTCT TC-3’. The resulting 268 bp amp-
lification product was restricted with NcoI and EcoRI and
inserted between the corresponding sites of pBADmychis-B
(Invitrogen, La Jolla, CA) to produce pBAD-H6-HCII1-75.
The resulting open reading frame encoded HCII codons
1-75, preceded by nine codons specifying MGSH6.
Construction of pBAD-H6HAPI T345R/M358R
In order to express an HCII 1-75-α1-PI M358R fusion pro-
tein incapable of forming a serpin-enzyme complex with
thrombin, the 5153 bp BstXI-EcoRI digestion product of
pBAD-H6HAPI M358R [19] was combined with the
361 bp fragment formed by digestion of pBAD-API T345R/
M358R [24], yielding plasmid pBAD-HAPI T345R/M358R.
Expression and purification of HCII 1-75
E. coli TOP10 cells (Invitrogen, La Jolla, CA) transformed
to ampicillin resistance with pBAD-H6-HCII1-75 were
grown in LB/ampicillin with shaking at 37°C to an OD600
of 0.5, prior to induction with arabinose to 0.002% (w/vol).
Following an additional 3.5 hours of growth, cells were
harvested by centrifugation and cell pellets disrupted by
sonication in equilibration buffer (EB; 50 mM sodium
phosphate pH 8.0, 300 mM NaCl, 10 mM imidazole), then
made 1% (vol/vol) in Triton X-100. The clarified lysate was
applied to nickel-nitrilotriacetic acid (Ni-NTA) agarose
resin (Qiagen, Carlsbad, CA), washed, and eluted with EB
containing 250 mM imidazole. Peak fractions were dia-
lyzed versus 20 mM Tris-Cl pH7.4, 200 mM NaCl, and
then chromatographed on Q-Sepharose (GE Healthcare,
Baie d’Urfe, QC). Proteins remaining bound after washes
with 20 mM Tris-Cl pH7.4, 300 mM NaCl were eluted
with 20 mM Tris-Cl pH7.4, 350 mM NaCl and concen-
trated with an Amicon Ultra-15 Centrifugal Filter Unit
with Ultracel-3 membrane (EMD Millipore, Billerica,
MA). The concentration of purified HCII 1-75 (and of all
other purified peptides and proteins employed in this
study) was determined by measuring the OD280 using a
spectrophotometer and the method of Edelhoch to esti-
mate the molar extinction coefficient based on the primary
sequence [25,26], which yielded a value of 33920 M-1cm-1.
Mass spectrometry
The mass of purified HCII 1-75 in a solution of 10 mM
Tris-Cl pH 7.4 was determined, using Matrix-Assisted
Laser Desorption Ionization Mass Spectrometry (MALDI
MS) by the Advanced Protein Technology Centre of the
Hospital for Sick Children (Toronto, ON).
Expression and purification of HCII-α1-PI fusion proteins
His-tagged recombinant proteins were purified from cell
lysates prepared from arabinose-induced E. coli TOP10
cells transformed to ampicillin resistance, either withpreviously described plasmid pBAD-H6HAPI M358R or
with the novel construct pBAD-H6HAPI T345R/M358R;
the same protocol was employed, involving Ni-NTA
agarose (Qiagen) and DEAE-Sepharose (GE Healthcare,
Baie d’Urfe, QC) chromatography of lysates from sonic-
ally disrupted bacteria as previously described [19].
Preparation of S195A-thrombin
S195A-thrombin was produced from purified prothrombin-
1 S195A expressed in Baby Hamster Kidney Cells (the gen-
erous gift of Dr. Timothy Mather, Oklahoma City, OK), as
previously described, using bovine prothrombinase diges-
tion and SP-Sepharose (GE Healthcare) chromatography
[27,28].
Gel-based analysis of serpin-enzyme complexes
Formation of HAPI-thrombin complexes was followed by
incubating 1 μM HAPI M358R or HAPI T345R/M358R
with 200 nM α-thrombin (Enzyme Research, South Bend,
IN) at 37°C for 1 minute prior to stopping the reaction
with one volume of 2X SDS-PAGE Loading Buffer
(0.16 M Tris-Cl pH 6.8, 4.4% (vol/vol) SDS, 20% vol/vol gly-
cerol, 0.2 M dithiothreitol, 0.4 mg/ml Bromophenol Blue)
and visualizing reaction products following SDS-PAGE as
described [22,29,30].
Thrombin binding assay
Purified HCII 1-75 was immobilized onto an Immulon 4
HBX 96 well microtiter plate (Thermo, Milford MA),
using a 1 μM solution of HCII 1-75 in PBS at 0.1 mL per
well overnight at 4°C. The HCII solution was then re-
moved and the wells blocked with 5% BSA (w/vol) in
PBS-T for one hour at ambient temperature. Following
washes with PBS-T, 0-100 nM α-thrombin in blocking
buffer was added to the wells and incubated at 37°C for
30 minutes. Wells were washed and reacted with horse-
radish peroxidase-conjugated sheep anti-human thrombin
antibody (Affinity Biologicals, Ancaster, ON), diluted 1:10,000
in blocking buffer, for one hour at ambient temperature. Fol-
lowing washes with PBS-T, colour was developed using a
freshly made solution of 5 mg o-phenylenediamine (Pierce)
in 12 mL of 25 mM citric acid, 97 mM Na2HPO4 pH5.0
supplemented with 0.03% (v/vol) hydrogen peroxide for ten
minutes prior to stopping the reaction with sulfuric acid.
The optical density at 490 nm was then read on an EL808
Plate reader (Biotek Instruments, Winooski, VT). In some
experiments, competitor peptides were added with the
thrombin; in others S195A-thrombin or thrombin inactivated
at its active site using D-Phe-L-Pro-L-Arg chloromethylke-
tone (FPR-ck, EMD Millipore, Billerica, MA) was substituted
for α-thrombin. Binding isotherms such as those shown in
Figure 1A were curve-fit for one-site binding (hyperbola)
using non-linear regression in GraphPad Prism 4.0 software
(GraphPad Software, La Jolla, CA). The same program was
Figure 1 Binding of different forms of thrombin to HCII 1-75
immobilized on microtiter plate wells. Binding of α-thrombin (α-IIa,
solid squares) or γT-thrombin (γT-IIa,▼) was measured as the optical
density (OD) at 490 nm as described in Materials and Methods, and
graphed relative to the mean OD of binding reactions carried out with
100 nM α-thrombin, taken as 100%, in Panel A. The mean ± the SD of
3 independent experiments is shown. Panel B shows the results of
experiments similar to those shown in Panel A, but carried out with
12.5 nM α-thrombin (α-IIa), S195A-thrombin (S195A-IIa), FPR-ck
-thrombin (FPR-ck-IIa) or γT-thrombin (γT-IIa); results were normalized
to the mean optical density (OD) at 490 nm observed for
α-thrombin binding. Each bar represents the mean ± the SD of 3
independent experiments; * indicates p<0.05 by non-parametric
ANOVA with Dunn’s post-test versus α-thrombin binding.
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in which HCII-derived or hirudin-derived peptides were
used to compete the binding of thrombin to immobilized
HCII 1-75. Inhibition plots such as those shown in Figure 2
were logarithmically transformed, lines of best fit solved by
linear regression, and the competitor concentration re-
ducing binding to 50% (IC50) was determined.
Thrombin clotting times
Thrombin times were determined using Thrombin 10
(freeze-dried human thrombin with calcium [1.5 NIH
units/mL] Diagnostica Stago, Asnieres, France) and an
STA 4 coagulation analyzer (Diagnostica Stago). Citrated
human plasma (25 μL) was combined with 75 μL veronal
buffer (7.14 mM sodium acetate trihydrate, 7.4 mMsodium diethyl barbiturate, 131 mM NaCl pH 7.4)
containing or lacking HCII- or hirudin-related peptides,
and clotting time was determined following the addition
of 100 μLThrombin 10 reagent.
Biotinylation of peptides and proteins
HCII- or hirudin-related peptides in 50 mM sodium phos-
phate pH 6.5 were combined with 20-fold molar excess
sulfosuccinimidyl-6-(biotinamido) hexanoate (sulfo-NHS-
LC-biotin, Pierce) at ambient temperature for 30 minutes.
Reactions were quenched with excess Tris-Cl pH 7.4 and
sulfo-NHS-LC-biotin removed by desalting or dialysis.
Biotinylated FPR chloromethylketone (bFPRck; Haemato-
logic Technologies, Essex Junction, VT) was used to mo-
dify α-thrombin at a bFPRck: thrombin molar ratio of 10:1 in
Tris-buffered saline (TBS, pH 7.4) for ten minutes at ambient
temperature. Excess reagent was removed by overnight dia-
lysis versus TBS. Thrombin biotinylated by bFPRck had
no detectable amidolytic activity against S2238.
Surface plasmon resonance
Surface plasmon resonance experiments were carried
out using a BIAcore X biosensor instrument (Biacore,
Piscataway, NJ) at 25°C. Biotinylated HCII- or hirudin-
related peptides were immobilized on streptavidin-coated
sensor chips (GE Healthcare) under conditions recommended
by the manufacturer. One flow cell contained bound peptide
and the other did not, serving as a reference cell to correct
for background binding effects. A flow rate of 2 μL/minute
was employed for immobilization runs, with 0.5 M NaCl
employed as a regeneration buffer and HEPES-buffered saline
(10 mM HEPES, 150 mM NaCl, 0.005% Tween-20, pH 7.7)
otherwise used for binding determinations. Binding of throm-
bin (0-30 μM) was assessed using 20 μL injection volumes,
and flow rates of 20 μL/minute. BIAcore Evaluation 3.2
(BIAcore) software was used to evaluate sensorgrams from
each run, using either 1:1 Langmuir binding or steady state
analysis. In some experiments various concentrations of
HCII- or hirudin-related peptides were combined with
250 nM thrombin or FPR-ck-thrombin immediately prior
to being flowed over chip-bound HCII 1-75.
Rate determinations for thrombin inhibition by plasma-
derived HCII
The apparent second-order rate constant (k2app) of
α-thrombin inhibition by purified plasma-derived
HCII (Affinity Biologicals, Ancaster, ON) was determined
under pseudo-first order conditions involving an excess of
plasma-derived HCII over α-thrombin using a discontinuous
assay as previously described [19,30], with or without
addition of competitor HCII 1-75, HCII 54-75, or HCII 1-53
at 0.25 mM. Briefly, plasma-derived HCII (140 nM) was in-
cubated with α-thrombin (14 nM) in PPNE buffer (20 mM
Na2HPO4, pH 7.4, 100 mM NaCl, 0.1 mM EDTA, 0.1%
Figure 2 Competition of binding of α-thrombin to HCII 1-75
immobilized on microtiter plate wells. Binding of α-thrombin was
measured as the absorbance at 490 nm as described in Figure 1,
and expressed as the ratio of the absorbance in the presence of
competitor (A) to that in its absence (Ao). Competitor peptides
identified to the right (panels A and B) or above (panel C) the
competition curve. The mean ± the SD of 3 independent
experiments is shown.
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(2 μM) standard heparin (Hepalean, Organon Teknika
Canada, St. Laurent, QC) and 10 μM S2238 (DiaPharma,
West Chester OH) or 0.055 mg/mL (1.4 μM) dermatan sul-
fate (Sigma-Aldrich, St. Louis, MO). Residual protease ac-
tivity was determined by diluting the reactions 100-foldinto 100 μM S2238 and measuring the absorbance at
405 nm for 5 minutes using an EL808 plate reader (BioTek
Instruments, Winooski, VT). From these data, pseudo
first-order and second-order rate constants were derived
as described, correcting for the presence of chromogenic
substrate in the first stage of the reaction [30].Molecular modelling of HCII 1-75
Molecular modeling of the first 75 amino residues of hu-
man HCII was performed using 3D-Jigsaw Comparative
Modeling software [31] in the automatic mode. This
software makes use of a threading algorithm dependent
on secondary structure prediction by PSIPRED [32]. The
predicted HCII1-75 molecular model fell within the 95th
percentile for expected structural accuracy (E value of
5.0 x 10-5). Structural superimposition was performed
with COOT [33]. Images were prepared with PyMol
(The PyMOL Molecular Graphics System, Version 1.2,
Schrödinger, LLC).Results
Expression and initial characterization of recombinant
HCII 1-75
We chose to express HCII 1-75 as a small recombinant
protein in E. coli because several laboratories have shown
that HCII 1-75 can fold appropriately when expressed in
E. coli in the context of the full HCII polypeptide
[7,30,34,35]. Moreover, this laboratory has shown that
HCII 1-75 retains the ability to interact with thrombin
when expressed in E. coli as part of HCII 1-75 - α1-PI
M358R fusion proteins [19]. As shown in Figure 3A, the
same sequence that was selected for use in the full-length
proteins was employed, such that an initiator Met codon
was followed by Gly-Ser codons introduced in the DNA
manipulations, 6 His codons, and the N-terminal 75 co-
dons of HCII. Inspection of total cellular protein pro-
files from E. coli harbouring plasmids encoding HCII
1-75 on Coomassie Blue-stained SDS PAGE gels revealed
an arabinose-inducible polypeptide of approximately
16 kDa (see Figure 3B, Ara- vs Ara+ lanes). This polypep-
tide bound to and eluted from nickel chelate columns
(Figure 3B); purification to homogeneity was achieved fol-
lowing polishing by ion exchange (Figure 3B, Q Sepharose
(QS) peak). Purified HCII 1-75 reacted both with anti-
hexahistidine and anti-HCII antibodies on ELISA (data
not shown). Because the mobility of this putative HCII
1-75 polypeptide differed from its theoretical full-length
molecular weight of 9624 Da, confirmation of its mass by
spectrometry was undertaken. MALDI mass spectrometry
revealed a single major peak corresponding to a mass/
charge ratio of 9494; this value is within one atomic mass
unit of the theoretical mass of HCII 1-75 lacking its initial
Met residue (9493) (data not shown). Taken together,
Figure 3 Schematic and electrophoretic representation of proteins and peptides employed in this study. Polypeptides comprising
portions of HCII (solid black bar, with residue numbers inset in white) or hirudin (Hir) (primary sequence shown) are represented schematically in
panel A. Each HCII-derived protein or peptide contains an N-terminal MGSH6 tag (shown at left of each schematic representation): Ac, acetyl;
SO3H, sulfate group on Hir Tyr63. Panel B shows a reduced 12% SDS polyacrylamide gel stained with Coomassie Brilliant Blue. Ara- and Ara+
lanes show total bacterial lysates from cultures expressing HCII 1-75 grown in the presence or absence of 0.002% (w/vol) arabinose. Aliquots of
bacterial lysates purified by nickel chelate chromatography (FT, flow-through; Ni, imidazole-eluted peak fractions; QS, final preparation polished by
ion exchange on Q-Sepharose) are shown. Approximately 0.75 μg of purified HCII 1-75 (QS), glutathione sulfotransferase (GST) and HAPI M358R
(HCII 1-75 α1-PI M358R fusion protein) were electrophoresed in the last three lanes at right. Panel C shows the reaction products of purified HAPI
M358R or HAPI T345R/M358R incubated with (+) or without (-) thrombin (IIa) electrophoresed on a reduced 12% SDS polyacrylamide gel stained
with Coomassie Brilliant Blue. The positions of molecular mass markers are labeled, in kDa, to the left of panels B and C; positions that are not
labeled due to insufficient space correspond to 160, 120, 100, 90, and 80 kDa.
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tide as recombinant HCII 1-75.
Expression of recombinant HCII 54-75 and synthesis of
HCII 54-75 and 1-53
Expression of recombinant HCII 54-75 was attempted
using an analogous approach to that employed for HCII
1-75. However, no arabinose-inducible proteins were
identified, either via SDS gel or immunoblot analysis of
either bacterial lysates or nickel chelate-selected proteins
(data not shown). We therefore obtained HCII 54-75 and
HCII 1-53 as synthetic peptides produced using custom
solid phase synthesis, as well as commercial synthetic
peptides corresponding to the acetylated C-terminal 11residues of hirudin variant 1 (Hir 55-65) or the tyrosine-
sulfated C-terminal dodecapeptide of hirudin variant 1
(sulfo-Hir 54-65) as shown schematically in Figure 3A.
Elimination of serpin activity of HAPI T345R/M358R
Fusion protein HAPI M358R contains the same sequence
as recombinant HCII 1-75 employed in this study, but
fused to the N-terminus of α1-PI M358R via a hexaglycine
spacer (19). In order to produce a variant of this protein
incapable of forming a covalent serpin-enzyme complex
with thrombin, in which interaction with thrombin could
occur only via the N-terminal HCII extension, we incorpo-
rated an additional T345R mutation into the protein, one
previously shown to inactivate α1-PI [36] and cell-surface
Figure 4 Effects of competitor peptides on thrombin clotting
time. Diluted citrated human plasma was recalcified in the presence
of thrombin and increasing concentrations of competitor peptides
identified to the right of each line (either HCII 1-75 or HCII 54-75
(panel A) or sulfo-Hir 54-65 or Hir 55-65 (panel B)). The mean ± the
SD of 3 independent experiments is shown.
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tion of purified HAPI M358R with thrombin led to the
formation of both a 100 kDa serpin-thrombin denaturation-
stable complex, and a 61 kDa cleaved form of the recom-
binant serpin; in contrast, the identical reaction carried
out with HAPI T345R/M358R led to the generation of
cleaved serpin alone.
Binding of different forms of thrombin to immobilized
HCII 1-75
An assay was developed to assess the binding of throm-
bin to HCII 1-75 immobilized on microtiter plate wells,
using an antibody to thrombin and enzymatic colour
generation linked to the antibody. In order to compare
the results of different experiments, results (shown in
Figure 1A) were normalized to the mean optical density
elicited by 100 nM concentrations of α-thrombin in all
replicated experiments. Binding was saturable (note the
lack of difference between binding elicited by 50 and 100
nM α-thrombin) and specific, since substitution of γT-
thrombin for α-thrombin eliminated binding (Figure 1A,
lower curve). γT-thrombin is a proteolyzed derivative of
α-thrombin in which most of thrombin exosite 1 has been
eliminated [9]. When the thrombin concentration was
fixed at 12.5 nM, below saturation on the binding curve
(Figure 1A), and binding of different forms of thrombin
was compared to that of α-thrombin, no difference in bind-
ing for S195A-thrombin or FRP-ck-thrombin was noted;
however, binding was significantly reduced, to minimal
levels, using γT-thrombin (Figure 1B). We did not further
analyse the binding from this assay, for instance in terms of
calculating a dissociation constant, because we had to dis-
card the unbound thrombin and add an antibody to deter-
mine the degree of binding, potentially changing the initial
binding isotherm. Nevertheless, our results suggested that
the assay reported specific binding of HCII 1-75 to throm-
bin exosite 1 and could be useful for initial experiments.
Competition for binding of thrombin to immobilized
HCII 1-75
We next compared the ability of different exosite 1 li-
gands to compete for binding of thrombin to HCII 1-75
immobilized on microtiter plate wells. Figure 2 shows
the results of these binding experiments, expressed as
the ratio of binding in the presence of competitor to
binding in its absence. Inspection of the competitive
binding curves shows that HCII 1-75 more effectively
competed its own binding to 5 nM thrombin than did
HCII 54-75 (Figure 2A), while sulfo-Hir 54-65 more ef-
fectively competed that binding than Hir 55-65; HAPI
T345R/M358R closely resembled HCII 1-75 as a competi-
tor (Figure 2C). The competitive binding curves were line-
arized by logarithmic transformation and the IC50s were
calculated for replicated experiments (see Methods). TheIC50s of the competitors, in order of decreasing affinity
(in μM, mean of 3 determinations ± SD), were found to be:
sulfo-Hir 54-65 (0.140 ± 0.040); Hir 55-65 (2.40 ± 0.30);
HAPI T345R/M358R (8.24 ± 0.33); HCII 1-75 (11.0 ± 4.0);
and HCII 54-75 (110 ± 20).Prolongation of thrombin clotting time by HCII and
hirudin peptides
An HCII 54-75 peptide had previously been shown to be
approximately 30-fold less potent than sulfo-Hir 54-65 as
an inhibitor of thrombin-mediated clotting of recalcified
human plasma [21]. We replicated this experiment and
extended it to include all four of the exosite 1 ligand pep-
tides employed in this study, as shown in Figure 4. We
used the measurement previously employed to judge the
potency of the peptides, the concentration required to
double the thrombin clotting time [21]. The following
order of efficacy as inhibitors of thrombin in plasma was
observed (in μM, mean of 3 determinations ± SD): sulfo-
Hir 54-65 (0.150 ± 0.02); Hir 55-65 (2.60 ± 0.40); HCII
1-75 (13.0 ± 1.7) and HCII 54-75 (72.0 ± 6.4).
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presence of heparin and HCII peptides
To compare the ability of the entire N-terminal acidic
extension of HCII to its constituent parts to compete for
plasma-derived HCII in inhibiting thrombin, the second
order rate constant of inhibition was determined in the
presence of heparin or dermatan sulfate, in a two-stage
reaction. The apparent reduction in this constant was
then determined, as shown in Figure 5A; when 250 μM
competitor peptide was added to 140 nM plasma-
derived HCII in the presence of 55 μg/mL standard he-
parin or dermatan sulfate, HCII 1-53 had no effect, while
HCII 1-75 reduced the apparent rate of inhibition to a
greater extent than HCII 54-75 (on average by 2.8-fold
versus 1.6-fold). The same pattern was seen in analogous
reactions in which 1.4 μM dermatan sulfate was employed
(Figure 5B), in that no reduction in the apparent rate of in-
hibition was elicited by HCII 1-53, but HCII 1-75 reduced
it 7.0-fold and HCII 54-75 only 1.6-fold.
Surface plasmon resonance
In order to facilitate immobilization on sensor chips for
surface plasmon resonance (SPR), HCII 1-75 was bio-
tinylated under conditions reported to favour modification
of its N-terminus, as opposed to amine-containing side
chains [38]. This modification did not appear to affect theFigure 5 Effects of HCII-derived peptides on the inhibition of
thrombin by plasma-derived HCII in the presence of GAGs. The
second-order rate constant of inhibition (k2) for the inhibition of 14
nM thrombin by 140 nM plasma-derived HCII was determined in the
presence of 55 μg/mL standard heparin (panel A) or dermatan
sulfate (panel B) in the absence (No Competitor) or presence of
competing peptides. The competing peptides that were used
separately at 250 μM were: HCII 1-75; HCII 54-75; or HCII 1-53. The
mean ± the SD of 3 independent experiments is shown.ability of the polypeptide to inhibit thrombin, since
11.7 μM biotinylated HCII 1-75 was required to double the
thrombin clotting time, a concentration not different from
that of the unmodified polypeptide (12.8 ± 1.0 μM) (data
not shown). Biotinylated HCII 1-75 was immobilized on
streptavidin-coated sensor chips, and binding resulting
from flowing different concentrations of thrombin over the
chip was observed by SPR as shown in the sensorgrams in
Figure 6A. Plotting the results of three independent ex-
periments and fitting the data to a one site binding
model yielded a KD of 340 ± 40 nM (mean ± SD). Substi-
tution of FPR-ck-thrombin for α-thrombin in analogous
SPR experiments gave similar KD values of 330 ± 60 nM
(data not shown).
Competition of thrombin binding to chip-immobilized
HCII 1-75
Having established thrombin binding conditions appro-
priate for quantitative analysis using chip-immobilized
HCII 1-75, we next assessed the ability of various pep-
tides to compete for that binding. Sensorgrams gener-
ated in the presence of increasing concentrations of
HCII 1-75, HCII 54-75, Hir 55-65 and sulfo-Hir 54-65
showed decreasing equilibrium binding of 250 nM
thrombin, as shown in Figure 6C through 6F. In con-
trast, addition of HCII 1-53 at concentrations up to
250 μM had no effect on thrombin binding to HCII 1-75
(data not shown). Using the mean KD of 340 nM deter-
mined above for α-thrombin and HCII 1-75 binding,
and IC50s determined by linear regression of the plotted
ratios of binding in the presence and absence of the dif-
ferent competitors, constants of inhibition (Ki) values
were determined. As shown in Table 1, HCII 54-75 was
less effective at competing thrombin binding than HCII
1-75, as indicated by its 3.3-fold higher mean Ki. Com-
bining equimolar HCII 54-75 and HCII 1-53 failed to re-
create the efficacy of HCII 1-75 as a competitor; the
combination was 1.5-fold less effective than HCII 54-75
in inhibiting thrombin binding. Both hirudin-derived
peptides were more effective competitors of thrombin
binding than HCII 1-75, by 9-fold (Hir 55-65) and 48-
fold (sulfo-Hir 54-65), respectively.
Discussion
Although multiple lines of evidence suggest that HCII
becomes conformationally activated by GAG binding,
leading to the release of the HCII 1-75 N-terminal acidic
extension and binding of thrombin exosite 1 [10-14,20],
little information was available concerning the affinity of
that binding prior to this study. This paucity of data
likely arose due to the difficulty of studying the inter-
action using either plasma-derived or recombinant HCII
molecules, which are capable both of forming non-
covalent links between HCII 1-75 and thrombin exosite
Figure 6 Senorgrams from surface plasmon resonance (SPR) experiments. Biotinylated HCII 1-75 was bound to streptavidin-coated sensor
chips and varying concentrations of thrombin were flowed over the chip, generating sensorgrams (e.g. Panel A) of the response in response
units (RU) versus the time in seconds. Panel B is a plot of experiment shown in Panel A, combined with two other independent experiments;
each point therefore represents the mean mid-plateau response ± the SD of 3 independent experiments. In panels C-F the thrombin
concentration was fixed at 250 nM and competitor peptides identified in each panel were combined with thrombin and flowed over the chip.
The concentration of competitor peptides in each experiment is shown to the left of the sensorgram.
Table 1 Dissociation constants for inhibition of thrombin
binding to HCII 1-75 (SPR)
Inhibitor Ki (μM)
HCII 1-75 2.6 ± 0.6
HCII 54-75 8.5 ± 2
HCII 1-53 No inhibition
HCII 54-75 and HCII 1-53 13 ± 3
Hir 55-65 0.29 ± 0.07
sulfo-Hir 54-65 0.054 ± 0.09
The mean of 3 determinations ± the standard deviation (SD) is shown.
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the serpin type with thrombin’s active site. To better
understand the role of the HCII acidic extension as a lig-
and of thrombin exosite 1, we first truncated recombin-
ant His-tagged HCII at residue 75. We employed the
same E. coli expression system we previously used to ex-
press HCII 1-75 fused to α1-PI M358R, because HCII 1-75
in that context appeared to bind thrombin exosite 1 [19].
Although purified recombinant MGSH6-tagged HCII
1-75 migrated less rapidly than expected on SDS-PAGE,
it displayed the expected mass by spectrometry; its atyp-
ical migration was likely due to its binding less SDS per
molecule than most proteins, as previously noted for fu-
sion proteins containing MGSH6-tagged HCII 1-75 [19].
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or 1-53 in E. coli suggested that HCII 1-75 was near the
lower size limit for efficient bacterial expression of
heterologous polypeptides [39]. We nevertheless ensured
appropriate comparisons by including MGSH6 in all
three HCII derivatives, whether obtained by bacterial ex-
pression or chemical synthesis.
Several lines of evidence suggested that our novel, bac-
terially expressed HCII 1-75 protein functioned as a
thrombin exosite 1 ligand. Firstly, it bound intact or active-
site modified thrombin, but not exosite 1-diminished γT-
thrombin, when immobilized either on microtiter plates or
sensor chips. Secondly, this binding was inhibited by pep-
tides whose ability to bind exosite 1 has been validated by
co-crystallization with thrombin (sulfo-Hir 54-65 [40] or
HCII 54-75 in intact HCII [20]). Thirdly, like HCII 54-75
or sulfo-Hir 54-65 peptides previously synthesized by other
investigators [8,21,41], it inhibited thrombin-induced
plasma clot formation. Finally, like HCII 54-75, it reduced
the apparent rate of thrombin inhibition by plasma-derived
HCII in the presence of GAGs. Taken together, our data
suggest that HCII 1-75 functioned as an exosite 1 ligand
and therefore resembled its native counterpart in intact
HCII, once the N-terminal extension had been liberated
from intramolecular interactions with the body of HCII by
GAG binding. HCII 1-75 understandably best represents
its native counterpart in recombinant HCII made in bac-
terial systems, rather than plasma-derived HCII, because of
the inability of bacteria to carry out the tyrosine sulfation
of Tyr60 and Tyr73 found in the natural protein [21].
Bacterially expressed forms of HCII nevertheless exhibit
similar maximal rates of thrombin inhibition to plasma-
derived HCII [7,29].
We employed surface plasmon resonance to determine
the KD of HCII 1-75 binding to thrombin, after confirming
that biotinylation of HCII 1-75 did not interfere with its
ability to delay the thrombin-induced clotting of plasma,
and binding the biotinylated HCII 1-75 to streptavidin-
coated sensor chips. Flowing either intact α-thrombin or
FPR-ck-thrombin over immobilized HCII 1-75 yielded in-
distinguishable values of 330 or 340 nM for the KD, as
expected if binding was mediated by exosite 1. While
there are no similar values in the literature available for
HCII 1-75 for comparison to our results, a 96 nM KD has
been reported for another thrombin exosite 1 ligand, the
C-terminal hirudin derivative sulfo-Hir 53-64 [42] (also
known as hirugen) [43]. Competition of thrombin binding
to chip-immobilized HCII 1-75 using either HCII 1-75
itself (Ki 2.6 μM) or non-sulfated Hir 55-65 (Ki 0.29 μM)
or sulfo-Hir 54-65 (Ki 0.054μM) confirmed both the su-
periority of the hirudin derivatives and the contribution of
tyrosine sulfation to their exosite 1 binding. Although pro-
ducing HCII 1-75 in E. coli prevented its tyrosine
sulfation, non-sulfated Hir 55-65 clearly bound exosite 1with higher affinity than HCII 1-75, showing that the su-
periority of the hirudin-derived peptides was manifested
by their polypeptide composition alone. Our data are con-
sistent with the previous finding that non-sulfated HCII
54-75 was 30-fold less potent than hirudin-derived, non-
sulfated peptides in either thrombin binding or clotting
assays [21].
As part of our dissection of the HCII acidic tail, we com-
pared HCII 1-75 to HCII 1-53 and HCII 54-75. HCII 1-53
had no detectable ability to bind thrombin, to delay
thrombin-mediated coagulation, or to compete for the
N-terminal HCII 1-75 extension in native HCII, mobilized
for exosite 1 binding by GAG activation. In contrast, HCII
54-75 had detectable activity in all of the above respects;
however, in each setting, it displayed lesser inhibitory po-
tency than HCII 1-75, consistent with its lesser ability to
compete for thrombin binding to chip-immobilized HCII
1-75 than free HCII 1-75 (compare Ki values of 2.6 to
8.5 μM). If HCII 1-53 does not bind to thrombin directly,
then the superiority of HCII 1-75 over HCII 54-75 would
seem most likely to derive from a conformational effect on
residues 54-75 that increases their ability to bind thrombin
in the way visualized in the S195A-thrombin-HCII struc-
ture [20]. Combining HCII 1-53 and HCII 54-75 in com-
petitive binding SPR experiments did not improve the
ability of the latter peptide to bind thrombin, suggesting
that the two regions must be present in the same polypep-
tide chain for this effect to occur. These results with iso-
lated HCII 1-75 and 54-75 are consistent with those
obtained when these sequences were fused to α1-PI, in that
fusion protein HAPI M358R (containing HCII 1-75)
inhibited thrombin at a rate 3.4-fold more rapid than fusion
protein H55-75API M358R (containing HCII 55-75) [19].
Alignment of human, rabbit, and mouse HCII primary
sequences (Figure 7) illustrates that human HCII contains
17 amino acids not found in the N-terminal regions of the
other mammalian HCII proteins; residues 8-24 of human
HCII have no counterpart in the other two sequences. As-
suming that the other HCII orthologues exhibit the same
mechanism of action as their human counterpart, and that
their far N-terminal sequences would also exert a con-
formational effect on residues 54-75, then the residues
exerting a conformational influence over HCII 54-75 in
HCII 1-75 and in fusion protein HAPI M358R should lie
between residues 25 and 53 of HCII. Residues 1-8 can be
discounted in this analysis given their relatively low degree
of identity.
Molecular modeling was employed to test these deduc-
tions. As shown in Figure 8A, the modeled HCII 1-75
structure, obtained using a threading algorithm dependent
on secondary structure predictions, contains random
coiled regions interspersed between three predicted α heli-
ces encompassing residues 4-12, 26-36, and 60-67. In
neither the HCII dimer crystal structure nor the HCII-
Figure 7 Alignment of N-terminal primary structures of human, rabbit, and mouse HCII. The N-terminal 75 residues of human (Homo sapiens,
Hs) HCII are shown, aligned with the corresponding residues from the other two mammalian HCII sequences (rabbit, Oryctolagus cuniculus, Oc,
and mouse, Mus muscularis, Mm). Dashes indicate no corresponding residue, while dots indicate that the residue is conserved across all three species.
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sidues N-terminal to Leu61 visible [20]; however, it was
possible to validate the model to a certain extent by
demonstrating that it fit the observed structures in theFigure 8 HCII 1-75 molecular model. (A) Molecular model of HCII residu
corresponding space filling model (grey). Helices are labeled 1, 2 and 3 cor
(B) Structural superimposition of helix 3 (purple) from the HCII 1-75 molecu
HCII crystal structure (PDB 1JMJ). HCII subunits are labeled HCIIa and HCIIb
included in the structural alignment are labeled. (C) Structural superimposi
complex determined by x-ray crystallography (PDB 1JMO). HCII, light green
purple; acidic residues used for structural alignment are shown in stick. Stesection of the acidic tail C-terminal to residue 61. As
shown in Figures 8A and 8B, the model structure de-
monstrated excellent agreement with both the native HCII
and HCII encounter complex crystal structure withes 1-75. HCII 1-75 is shown in ribbon representation (purple) and
responding to residues 4-12, 26-36 and 60-67 of HCII, respectively.
lar model with the same region of HCII (yellow) observed in the apo-
and colored green and cyan, respectively. Amino acid residues of HCII
tion of HCII 1-75 molecular model with the HCII-thrombin encounter
; HCII residues 54-73 are shown in yellow; thrombin, cyan; HCII 1-75,
reogram images are shown in all cases.
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HCII interface. In this context, the model predicts an
interaction between helices 2 and 3, which are in a similar
plane in three dimensions, as opposed to helix 1, which is
canted forward in the stereograms depicted in Figure 8.
The predicted interaction of residues 26-36 with residues
60-67 is consistent with our findings both with small poly-
peptides comprising HCII 1-75 and HCII 54-75 (this study)
and with fusion proteins in which these portions of the
acidic tail were fused with α1-PI M358R [19]. Why this
effect has not been noted with truncation mutants of re-
combinant HCII expressed in either bacterial or
baculoviral expression systems [7,44] is not clear. Dele-
tion of residues 1-52 did not change the rate constants
for thrombin inhibition either with or without GAG ca-
talysis with untagged recombinant HCII produced using
these systems. However, deletion of the first 52 amino
acids of recombinant HCII led to a statistically significant,
2-fold reduction in the rate of thrombin inhibition, when
wild-type and deletion mutant were both furnished with a
C-terminal hexahistidine tag to facilitate purification of
the baculovirally expressed proteins [44]. It is also possible
that helix 3 is indirectly stabilized by other interactions in-
volving residues in HCII C-terminal to the acidic tail, in
the context of truncation mutants of HCII, such that the
contribution of the putative helix2 – helix 3 interaction
can be best observed when studying the acidic extension
in the non-native context.
The relative contributions to HCII function of a template
mechanism, in which thrombin and HCII become co-
localized due to their binding to the same glycosaminogly-
can chain, or a conformational change mechanism, in which
GAG binding to HCII releases the N-terminal extension of
HCII for exosite 1 binding, remain somewhat controversial
[12,15], as does the degree of cross-talk between thrombin’s
exosites and active site [45-47]. Nevertheless, reported KD
values for thrombin binding to dermatan sulfate (2-6 μM)
[47] are much less than that for the HCII-dermatan sulfate
interaction (236 – 290 μM) [47] but higher than those
reported in this study for HCII 1-75 binding to exosite 1
(0.34 μM). Even if, as was the case with the hirudin
dodecapeptide, the lack of tyrosine sulfation on HCII 1-75
caused us to overestimate the 1-75: exosite 1 affinity in na-
tive HCII by 5- to 10-fold, this would not change the relative
order of affinities. The same order of affinities has been
reported when considering high molecular weight heparin
rather than dermatan sulphate as the GAG [47]. These rela-
tive binding affinities support a mixed mechanism in which
thrombin binds GAG and HCII then binds to the thrombin-
GAG complex, undergoing a conformational change which
liberates HCII 1-75, which then binds thrombin via exosite 1
more tightly than either reactant binds to GAGs, setting the
stage for physiologically irreversible inhibition of thrombin
via the serpin suicide-substrate mechanism.Conclusions
In this study we have characterized the thrombin exosite 1
ligand, the N-terminal acidic extension of HCII, to a degree
not previously possible, by expressing it in isolated form. It
bound thrombin with a higher affinity than GAGs, as indi-
cated by its KD for thrombin binding of 330-340 nM, and
bound more effectively than HCII 54-75; HCII 1-53 did not
bind to thrombin. Molecular modelling suggested a struc-
tural explanation for a contribution of residues N-terminal
to residue 52 in stabilizing the more C-terminal portions of
this unique serpin acidic tail; we hypothesize that this
model reflects the structure not only of isolated HCII 1-75
but also that region of the intact protein in GAG-activated
form. The latter working hypothesis may be tested in future
studies by site-directed mutagenesis, now that procedures
have been established for expression, purification, and
characterization of this exosite-1- binding motif as an iso-
lated polypeptide.
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